▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1673 by analyst upside · 2026-09-27
NRIX
Nurix Therapeutics, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+47.5%
implied upside to consensus target
Current Price $23.01
Consensus Target $33.93
Bull Target $45.0
Bear Target $25.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
8
Hold
1
Sell
0
52-Week Low $8.85
52-Week High $28.23
YTD Return +27.4%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.46
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $37M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.85
52-Week High $28.23
Current Price $23.01
Bear Target $25.0
Bull Target $45.0
● Now $23.01 ● Target $33.93
TRADING DATA
Avg Volume 1.3M
YTD Return +27.4%
Analyst Count 14
Consensus Buy
Upside to Target +47.5%
Last Updated 2026-09-27

ANALYST SUMMARY

Nurix Therapeutics, Inc. (NRIX) is currently trading at $23.01 with a Wall Street consensus price target of $33.93, implying potential upside of 47.5% over the next 12 months. 14 analysts currently cover NRIX, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $45.0, while the most cautious has a target of $25.0.

NRIX operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 27.4% year-to-date and is currently trading near the upper end of its 52-week range of $8.85 – $28.23.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for NRIX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital - Reiterated
Outperform → Outperform 2026-08-10 Building track record
Needham reit
Buy → Buy 2026-08-04 20% win rate (5 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-07-28 Building track record
UBS - Reiterated
Buy → Buy 2026-07-22 33% win rate (6 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-07-13 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-07-10 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-07-10 Building track record
Stifel - Reiterated
Buy → Buy 2026-07-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
56
out of 100
Coverage depth
21/30
Consensus clarity
13/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →